Myriad Genetics, Inc.
MYGN
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $301.3M
$3.19
▼ -1.24%
P/E
-2.68
Mkt Cap
$301.3M
52-Wk Range
$2.74–$8.59
52-Week Range
$2.74 - $8.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 53.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Extensive proprietary test portfolio with strong clinical validation and market recognition
- FDA-approved companion diagnostic tests integrated into cancer treatment pathways
- Strategic partnerships with Illumina and Intermountain Precision Genomics expanding capabilities
- Established relationships with oncologists, OB/GYNs, and mental health providers
- Decades of genetic testing expertise and data accumulation since 1991 founding
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Stable outlook
Premium gross margins (70%)
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Falling
-27.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MYGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
JUL 30, 2026
Reported EPS of -$0.25 vs -$0.06 consensus (-331.9% surprise). Revenue of $190.7M vs $206.0M expected (-7.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-331.9%
Revenue trend · last 8Q
—
+7%
-3%
+1%
-4%
-0%
+2%
-11%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$213.3M
$210.6M
$195.9M
$213.1M
$205.7M
$209.8M
$200.4M
$190.7M
Margins · last 8Q
Gross
66.6%
Operating
-20.4%
Profit
-22.6%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
67%
Sell
33%
Median Price Target
—
Latest: Piper Sandler · Sep 1, 2026
vs Industry
How MYGN stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related